Search Within

Michael John Mauro

Formats
  1. Meeting Abstract (188)
  2. Journal Article (67)
  3. Review (8)
  4. Correspondence (4)
  5. Research Letter (3)
  6. Book Section (2)
  7. Editorial (2)
  8. Guidelines (2)
Groups
  1. Adult Leukemia (276)
  2. Center for Hematologic Malignancies (276)
  3. Department of Medicine (276)
  4. Hematologic Malignancies, Division of (276)
  5. Biostatistics Service (10)
  6. Epidemiology and Biostatistics (10)

More Groups

People
  1. Raajit Rampal (12)
  2. Ellin Berman (8)
  3. Eytan Stein (8)
  4. Martin Tallman (7)
  5. Amber King (6)
  6. Andriy Derkach (6)

More People

Years
  1. 2025 (7)
  2. 2024 (17)
  3. 2023 (26)
  4. 2022 (33)
  5. 2021 (21)
  6. 2020 (26)

More Years

Publications
  1. Blood (97)
  2. Clinical Lymphoma, Myeloma and Leukemia (44)
  3. Journal of Clinical Oncology (22)
  4. Haematologica (21)
  5. Leukemia (12)
  6. American Journal of Hematology (8)

More Publications

Publishers
  1. American Society of Hematology (101)
  2. Elsevier Inc. (47)
  3. American Society of Clinical Oncology (22)
  4. Ferrata Storti Foundation (21)
  5. Nature Publishing Group (13)
  6. John Wiley & Sons (8)

More Publishers

Results (276)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysis
    Correspondence

    Kockerols, C.; Valk, P. J. M.; Dulucq, S.; Nicolini, F. E.; Mahon, F. X.; Atallah, E.; Mauro, M. J.; Radich, J. P.; Bernardi, S.; Russo, D.; more...
    American Journal of Hematology (2024)

    Fulltext@MSK | Save
  • Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
    Journal Article

    Jabbour, E.; Apperley, J.; Cortes, J.; Rea, D.; Deininger, M.; Abruzzese, E.; Chuah, C.; DeAngelo, D. J.; Hochhaus, A.; Lipton, J. H.; more...
    Leukemia (2024)

    Fulltext@MSK | Save
  • CML and the WHO: Why?
    Editorial

    Berman, E.; Shah, N. P.; Deninger, M.; Altman, J. K.; Amaya, M.; Begna, K.; Bhatia, R.; Chan, O.; Collins, R.; Curtin, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Project confirm: Accelerated drug approvals for CML—Response
    Correspondence

    Sweet, K. L.; Cortes, J. E.; Apperley, J. F.; Mann, M.; Mauro, M. J.; Oehler, V. G.; Ruiz, C.; Schiffer, C. A.; Ehrlich, L. A.; Pamuk, G. E.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Sustained efficacy and safety with asciminib (ASC) after almost 4 years of median follow-up from ASCEMBL, a phase 3 study of ASC vs bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): An end of study treatment (EOS Tx) update, including results from switch population
    Meeting Abstract

    Mauro, M.; Minami, Y.; Hochhaus, A.; Lomaia, E.; Voloshin, S.; Turkina, A.; Kim, D. W.; Apperley, J. F.; Cortes, J.; Abdo, A. N. R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • HJKC3-0006: Outcome of patients with CML treated on second line or later therapy in routine clinical practice
    Meeting Abstract

    Thompson, J. E.; Gao, Y.; Visotcky, A.; Flynn, K. E.; Mauro, M.; Giever, E.; Baim, A.; Akinola, I.; Larson, R.; Jamy, O.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • HJKC3-007: Outcomes of patients with chronic myeloid leukemia in chronic phase treated with asciminib and other tyrosine kinase inhibitors in routine clinical practice
    Meeting Abstract

    Mauro, M.; Atallah, E. L.; Thompson, J. E.; Gao, Y.; Visotcky, A.; Giever, E.; Baim, A.; Akinola, I.; Larson, R. A.; Jamy, O.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Long-term results from the OPTIC trial: A dose-optimization study of 3 starting doses of ponatinib
    Meeting Abstract

    Cortes, J.; Deininger, M.; Lomaia, E.; Moiraghi, B.; Undurraga, S.; Pavlovsky, C.; Chuah, C.; Sacha, T.; Lipton, J. H.; McCloskey, J.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • ASC2ESCALATE: A US phase 2, open-label, single-arm, dose-escalation study of asciminib (ASC) monotherapy in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) as second-line (2L) and first-line (1L) treatment
    Meeting Abstract

    Atallah, E. L.; Mauro, M.; Sasaki, K.; Levy, M.; Koller, P. B.; Yang, D.; Laine, D.; Sabo, J.; Gu, E.; Cortes, J.
    Blood (2023)

    Fulltext@MSK | Save
  • A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Meeting Abstract

    Bewersdorf, J. P.; Derkach, A.; Masarova, L.; Pemmaraju, N.; Stein, E. M.; Mauro, M.; Rampal, R. K.; Bose, P.
    Blood (2023)

    Fulltext@MSK | Save